Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous IFNγ-stimulated mesenchymal stromal cells
- Development stage
- Unknown
- Lead developer
- University of Wisconsin–Madison
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraglandular
01
Overview
Autologous IFNγ-stimulated mesenchymal stromal cells, also known as MSC(M), are an investigational cell therapy being developed for the treatment of radiation-induced xerostomia (RIX) in head and neck cancer patients. The manufacturing process involves harvesting bone marrow-derived mesenchymal stromal cells (MSCs) from the patient, expanding them in vitro, and "licensing" them with interferon-gamma (IFNγ). This stimulation enhances the cells' immunomodulatory and regenerative properties, notably increasing the expression of indoleamine 2,3-dioxygenase (IDO). The cryopreserved cells are thawed and injected directly into the patient's submandibular glands to promote tissue repair and restore salivary function. The therapy is currently being evaluated in the Phase 1 MARSH trial (NCT04489732) at the University of Wisconsin-Madison.
- Other names
- autologous interferon-gamma-stimulated mesenchymal stromal cellsIFNγ-stimulated MSCsmarrow-derived autologous stromal cells
Beyond the preview
Go deeper on autologous IFNγ-stimulated mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous IFNγ-stimulated mesenchymal stromal cells.